1 / 1

Abstract ID: 3540

Prospective study of EGFR intron 1 CA tandem repeats as predictive factor of benefit from cetuximab and irinotecan

kirima
Download Presentation

Abstract ID: 3540

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prospective study of EGFR intron 1 CA tandem repeats as predictive factor of benefit from cetuximab and irinotecan Antoniotti C 1, 2, Loupakis F 3, Cremolini C 1, 2, Zhang W 3, Yang D 3,Wakatsuki T 3, Schirripa M 1, 2, Salvatore L 1, 2, Ricci V 4, Graziano F 5, Masi G 1 ,2, Ruzzo A 6, LaBonte MJ 3, Ning Y 3, El-Khoueiry R 3,Falcone A1,2, Lenz HJ 3 1. U.O. OncologiaMedica 2 Universitaria, AziendaOspedaliera-UniversitariaPisana, Pisa, Italy; 2. Istituto Toscano Tumori (ITT), Italy; 3. Department of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA;4. UnitàdiOncologia, IstitutoScientifico San Raffaele, Milano, Italy; 5. Medical Oncology Unit, Hospital of Pesaro, Pesaro, Italy; 6. Section of Biochemistry and Molecular Biology, Department of Biomolecular Sciences, University of Urbino, Urbino, Italy Abstract ID: 3540 Patients and Methods Background Results At a median f-up of 21.9 mos, mPFS and mOS were 5.2 and 13.4 mos, respectively. EGFR (CA)n genotype was L- and SS in 45 (40%) and 68( 60%) pts respectively. Ten (22%) out of 45 L- pts achieved response compared to 22 (33%) out of 67 SS pts (Fisher’s Exact test: p=0.617). No differences in PFS or OS were observed between L- and SS genotypes mPFS: 4.4 versus 5.3 mos, HR: 1.00 [95%CI: 0.67-1.51], p=0.991; mOS: 11.3 versus 14.2 mos, HR: 1.30 [95%CI: 0.80-2.22], p=0.261. We designed a prospective confirmatory study in KRAS and BRAF wild-type irinotecan-resistant mCRC patients treated with biweekly cetuximab and irinotecan in advanced lines. We defined S and L allelic variants those presenting < and ≥ 20 CA repeats, respectively. To detect a HR for PFS of 1.75 for L- compared to SS genotypes, estimating a prevalence of 60% of SS variant and setting a two-sided alfa=0.05 with a power of 80%, 104 events were required . Preclinical data suggest that the number of CA tandem repeats in EGFR intron 1 might affect gene transcription. Different retrospective studies have investigated the impact of the number of EGFR intron 1 CA repeats on the efficacy of cetuximab in mCRC patients, providing contrasting results. As reported below, different cut-off values were adopted to define polymorphic variants and patients with heterogeneous clinical and molecular characteristics were included. MAIN PATIENTS’ CHARACTERISTICS Other exploratory analyses adopting different cut-off values reported in literature led to similar results. Conclusions This prospective study, including a clinically homogenous and molecularly selected population, does not confirm any predictive or prognostic effect for EGFR (CA)n repeat allelic variants with respect to the efficacy of cetuximab and irinotecan in advanced lines of treatment. The present experience strengthens the need of prospectively challenging retrospective findings, to validate apparently promising biomarkers. carlottantoniotti@gmail.com

More Related